Pharmafile Logo

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

January 29, 2020 |  

Written by Gavin Jones, OPEN Health

The FDA has published their industry guidance on the topic of long term follow up (LTFU) post gene therapy. Please see a link to the full guidance below. In summary, they are stipulating that a good proportion of these therapies will require LTFU of up to fifteen years.

This presents significant challenge to manufacturers given that patients will, in that stretch of time, have multiple changes to their care settings and life circumstances. In addition to this, and if these therapies live up to their promise, treated ‘patients’ will potentially become chronically well and keen to disengage from their previous disease state and their healthcare professionals.

This is a significant challenge but achievable! We have already shared our experienced thinking on this topic and a link to our article is provided below. Our recommendations focus on putting the patient at the centre of a solution and wrapping a, digitally enabled, registry solution around thoughtful patient and healthcare professional engagement.

Please read our full thinking below:

http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=5cf08b2f-f3d9-435a-8255-ef07542eb9a3&pnum=31

https://www.fda.gov/media/113768/download

Pink divider

Get in touch

If you would like to discuss further please contact our director of rare disease: gavinjones@openhealthgroup.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

OPEN Health Appoints Tim Perryman as Global Head of Operations to Strengthen Operational Excellence and Support Global Growth

OPEN Health today announced the appointment of Tim Perryman as Global Head of Operations, strengthening the company’s operational leadership as it continues to scale its global capabilities and support clients...

OPEN Health Appoints Peter Black as EVP, Global Client Partner and Transformation Lead to Accelerate Global Client Partnerships and Digital Innovation

OPEN Health today announced the appointment of Peter Black as EVP, Global Client Partner and Transformation Lead.

OPEN Health Appoints Cara Priest as Chief People Officer to Strengthen Culture, Capability and Organisational Performance

OPEN Health today announced the appointment of Cara Priest as Chief People Officer, reinforcing the company’s commitment to building a high-performing culture that supports its continued growth and scientific excellence.

OPEN Health Appoints Matt D’Auria as Chief Executive Officer to Drive Innovation and Growth

OPEN Health Group is pleased to announce the appointment of Matt D’Auria as its new Chief Executive Officer (CEO). Based in the US, Matt brings more than 25 years of...

OPEN Health Appoints David Sakadelis as Chief Technology Officer

OPEN Health is pleased to announce the appointment of David Sakadelis as Chief Technology Officer. In this role, David will be responsible for enhancing our services through technology-enabled solutions for...

The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy

Discover the key takeaways from OPEN Health’s latest whitepaper: "The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy."

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

OPEN Health is excited to announce the upcoming presentation of a collection of research supported by its Scientific Buyout Program. This initiative empowers our team members to dedicate time toward...

OPEN Health and fusion announce partnership to deliver AI-powered healthcare communications

OPEN Health, a pre-eminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting, today announced a partnership with fusion, an innovative artificial intelligence (AI) and machine...

OPEN X Health launches to provide data-driven creativity to the pharmaceutical industry

OPEN X Health launches to provide data-driven creativity to the pharmaceutical industry

OPEN Health Appoints Steven Duryee as Chief Operating and Transformation Officer

OPEN Health Appoints Steven Duryee as Chief Operating and Transformation Officer